Royce & Associates LP Makes New $407,000 Investment in LeMaitre Vascular, Inc. (NASDAQ:LMAT)


Royce & Associates LP added a new position in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT – Get Rating), according to its recent SEC filing during the first quarter. The fund acquired 8,757 shares of the medical instrument maker for approximately $407,000.

Several other major investors have also recently bought and sold shares in the company. Conestoga Capital Advisors LLC increased its holding in LeMaitre Vascular by 1.2% during the first quarter. Conestoga Capital Advisors LLC now owns 1,879,847 shares of the medical instrument maker worth $87,357,000 after purchasing an additional 22,663 shares last quarter. Copeland Capital Management LLC increased its ownership of LeMaitre Vascular shares by 0.8% during the first quarter. Copeland Capital Management LLC now owns 1,215,005 shares of the medical instrument maker worth $56,461,000 after purchasing an additional 9,806 shares last quarter. Ranger Investment Management LP increased its holdings of LeMaitre Vascular shares by 1.6% during the fourth quarter. Ranger Investment Management LP now owns 646,999 shares of the medical instrument maker, valued at $32,499,000, after purchasing an additional 10,010 shares last quarter. Summit Creek Advisors LLC increased its holding in LeMaitre Vascular by 21.0% during the fourth quarter. Summit Creek Advisors LLC now owns 361,359 shares of the medical instrument maker, valued at $18,151,000, after purchasing an additional 62,754 shares last quarter. Finally, Grandeur Peak Global Advisors LLC increased its holding in LeMaitre Vascular shares by 0.9% during the fourth quarter. Grandeur Peak Global Advisors LLC now owns 314,076 shares of the medical instrument maker valued at $15,776,000 after purchasing an additional 2,931 shares last quarter. 84.90% of the shares are currently owned by hedge funds and other institutional investors.

Changes in analyst ratings

Separately, Barrington Research lowered its price target on LeMaitre Vascular to $50.00 from $54.00 in a report on Friday, April 29.

Performance of LeMaitre Vascular stock

LMAT opened at $53.24 on Friday. LeMaitre Vascular, Inc. has a yearly low of $38.32 and a yearly high of $60.79. The stock has a market cap of $1.17 billion, a P/E of 52.71, a P/E of 4.66, and a beta of 1.20. The company’s 50-day moving average price is $46.43 and its 200-day moving average price is $45.13.

LeMaitre Vascular announces dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, September 8th. Investors of record on Thursday, August 25 will receive a dividend of $0.125. That equates to an annual dividend of $0.50 and a yield of 0.94%. The ex-dividend date of this dividend is Wednesday August 24th. LeMaitre Vascular’s payout ratio is currently 49.51%.

LeMaitre Vessel Profile

(get rating)

LeMaitre Vascular, Inc develops, markets, sells, services and supports medical devices and implants used to treat peripheral vascular diseases worldwide. It offers an angioscope, a fiber optic catheter used to view the lumen of a blood vessel; embolectomy catheters for removing blood clots from arteries or veins; occlusion catheters, which temporarily occlude blood flow; perfusion catheters for perfusing blood and other fluids into the vascular system; and thrombectomy catheters having a silicone balloon for removing thrombi in the venous system.

See also

Want to see what other hedge funds are holding LMAT? Visit HoldingsChannel.com for the latest 13F filings and insider trades for LeMaitre Vascular, Inc. (NASDAQ:LMAT – Get Rating).

Institutional Ownership by Quarter for LeMaitre Vascular (NASDAQ:LMAT)



Receive news and reviews for LeMaitre Vascular Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for LeMaitre Vascular and related companies with MarketBeat.com’s FREE daily email newsletter.

Leave a Comment

Your email address will not be published.